EUCTR2008-006333-27-CZ进行中（未招募）不适用
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Sclerosis - ADVANCE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible to participate in this study, candidates must meet the following eligibility riteria at the time of randomization, Day 1:
- •1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
- •2. Aged 18 to 65 years old, inclusive, at the time of informed consent.
- •3. Must have a confirmed diagnosis of relapsing MS, as defined by McDonald criteria #1-4.
- •4. Must have an EDSS score between 0.0 and 5.0.
- •5. Must have experienced at least 2 relapses that have been medically documented within the last 3 years with at least one of these relapses having occurred within the past 12 months prior to randomization (Day 1).
- •6. All male subjects and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 3 months, after their last dose of study treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 75
排除标准
- •Candidates will be excluded from study entry if any of the following exclusion criteria exist at the time of randomization, Day 1: Medical History
- •1. Primary progressive, secondary progressive, or progressive relapsing MS (as defined by Lublin and Reingold, 1996). These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Subjects with these conditions may also have superimposed relapse, but are distinguished from relapsing subjects by the lack of clinically stable periods or clinical improvement.
- •2. History of severe allergic or anaphylactic reactions or known hypersensitivity.
- •3. Prior treatment with interferon cannot exceed 4 weeks and subjects must have discontinued interferon treatment 6 months prior to Baseline.
- •4. Known allergy to any component of the BIIB017 formulation.
- •5. History of any clinically significant (as determined by the Investigator) cardiac,
- •endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary,
- •neurologic, dermatologic, psychiatric, and renal, or other major disease that would preclude participation in a clinical trial.
- •6. History of malignant disease, including solid tumors and hematologic malignancies
- •(with the exception of basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured).
- •7. History of seizure disorder or unexplained blackouts OR history of a seizure within 3 months prior to Baseline.
- •8. History of suicidal ideation within 3 months prior to Baseline or an episode of severe depression within 3 months prior to Baseline. Severe depression is defined as an episode of depression that requires hospitalization, or at the discretion of the Investigator.
- •9. Clinically significant abnormal electrocardiogram (ECG) values as determined by the Investigator.
- •10. Known history of Human Immunodeficiency Virus (HIV).
- •11. Known history or positive test result for hepatitis C antibody (HCV Ab), or current hepatitis B infection at Screening. Subjects with immunity to hepatitis B from either active vaccination or from previous natural infection are eligible to participate in the study
- •12. Abnormal screening blood tests exceeding any of the limits defined below:
- •Alanine transaminase/serum glutamate pyruvate transaminase (ALT/SGPT) greater than 2 times the upper limit of normal (>2 × ULN) or aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) >2 × ULN or bilirubin >1.5 × ULN.
- •Total white blood cell count (WBC) <3,700 /mm3
- •Absolute Neutrophil Count (ANC) of < 1,500 /mm3
- •Platelet count <150,000 c/mm3
- •Hemoglobin <10 g/dL in female subjects; <11 g/dL in male subjects
- •Serum creatinine >ULN
- •Prothrombin time (PT) or activated partial thromboplastin time (aPTT) >1.2 × ULN
- •13. An MS relapse that has occurred within the 50 days prior to randomization and/or the subject has not stabilized from a previous relapse prior to randomization (Day 1).
- •Treatment history:
- •14. Any previous treatment with BIIB017.
- •15. History of hypersensitivity or intolerance to acetaminophen (paracetamol), ibuprofen, naproxen, or aspirin that would preclude use of at least one of these during the study.
- •16. Treatment with other agents to treat MS symptoms or underlying disease as specified in Table P.43 in protocol.
- •17. Treatment with another investigational drug or approved therapy for investigational use within the 6 months prior to randomization (Day 1
研究者
相似试验
未知
3 期
A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-385 40 mg compared with Leuprorelin in the Treatment of Uterine Fibroidsterine fibroidJPRN-jRCT2080223074Takeda Pharmaceutical Company Limited288
进行中（未招募）
1 期
A clinical trial of TEV-48125 to evaluate long term safety, tolerability and efficacy for the Preventive Treatment of MigraineEpisodic and Chronic MigraineMedDRA version: 20.0 Level: LLT Classification code 10066636 Term: Chronic migraine System Organ Class: 100000004852MedDRA version: 20.0 Level: LLT Classification code 10027602 Term: Migraine headache System Organ Class: 100000004852EUCTR2015-004550-18-FITeva Branded Pharmaceutical Products R&D, Inc.1,890
进行中（未招募）
不适用
A Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple SclerosisEUCTR2008-006333-27-EEBiogen Idec Limited1,500
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Crohn's DiseaseCrohn's DiseaseEUCTR2020-004775-40-LVArena Pharmaceuticals Inc.1,265
进行中（未招募）
1 期
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Patients Who Did Not Respond to Prior Preventive Migraine Treatmentsepisodic and chronic migraineMedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 100000004852EUCTR2017-002441-30-SETeva Branded Pharmaceutical Products R&D, Inc.838